RELAPSING MULTIPLE SCLEROSIS

This study follows adults with multiple sclerosis (MS) for about 3 years to check the long-term safety of the drug tolebrutinib. It includes 2,500 people who were already in earlier trials for this medication. The main goal is to monitor for side effects and see how well people t…

This study examines whether starting the medication ocrelizumab very early after a first MS symptom changes markers of inflammation in the spinal fluid. It involves 30 newly diagnosed adults who will receive the drug every 6 months for 3 years. The goal is to see if early, strong…

This study is testing whether an experimental drug called fenebrutinib can reduce new areas of inflammation in the brain for people with relapsing multiple sclerosis (RMS). About 109 participants were randomly assigned to receive either fenebrutinib or a placebo pill for 12 weeks…

This study is testing whether an experimental drug called remibrutinib works better than an existing medication (teriflunomide) for people with relapsing multiple sclerosis. About 1,000 participants will take one of these medications for up to 30 months, with the option to contin…

This study is testing whether the drug Ocrevus can improve walking, balance, and leg strength in people with relapsing multiple sclerosis (MS) over one year. It will compare 60 participants taking Ocrevus to others taking different standard MS medications. Researchers will measur…

This study observes people with relapsing multiple sclerosis in Austria to see if starting the drug Ofatumumab (Kesimpta) early in their disease journey leads to better outcomes than starting it later. It follows 106 patients for two years, comparing those who start the drug soon…

This large Phase 3 study is testing whether a new oral drug called remibrutinib works better and is as safe as an existing standard oral medication (teriflunomide) for adults with relapsing multiple sclerosis (RMS). About 1011 participants will take one of the two drugs for up to…

This large, late-stage study is testing whether a new oral drug called fenebrutinib works better and is as safe as the established drug teriflunomide for adults with relapsing multiple sclerosis (RMS). About 750 participants are randomly assigned to take one of the two pills to s…

This large, late-stage study is testing whether an experimental oral drug called fenebrutinib works better and is as safe as an approved medication, teriflunomide, for adults with relapsing multiple sclerosis (RMS). About 746 participants will be randomly assigned to take one of …

This study aims to collect long-term safety and effectiveness data for the drug ofatumumab in people with relapsing multiple sclerosis (MS). It follows nearly 1,900 patients who previously participated in a Novartis MS study to monitor their health over an extended period. The re…

This study is testing whether a new injectable medication called obexelimab can help control relapsing multiple sclerosis. It will involve 93 people with MS who will receive either the drug or a placebo for 12 weeks, followed by a longer period where everyone gets the drug. Resea…